If the last couple of days is an indication, 2022 is already shaping up to be the year of big-ticket alliances between big pharma companies and specialists in artificial intelligence-driven discovery.

Sanofi's rash of dealmaking has continued with a $2.5 billion tie-up with Chinese cancer immunotherapy biotech Adagene, focused on developing a new generation of safer antibody-based therapies.

After hours: February 14 at 6:58:19 PM EST Loading Chart for SNY ...

Official Action Indicated (OAI). Not many investors may have heard of this. But they would surely have felt its impact. For, the moment OAI is triggered, the stock price slips sharply. OAI is nothing ...